These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32271353)

  • 1. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.
    Gonzalez-Cao M; Morán T; Dalmau J; Garcia-Corbacho J; Bracht JWP; Bernabe R; Juan O; de Castro J; Blanco R; Drozdowskyj A; Argilaguet J; Meyerhans A; Blanco J; Prado JG; Carrillo J; Clotet B; Massuti B; Provencio M; Molina-Vila MA; Mayo de Las Casa C; Garzon M; Cao P; Huang CY; Martinez-Picado J; Rosell R
    JAMA Oncol; 2020 Jul; 6(7):1063-1067. PubMed ID: 32271353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
    Powles T; O'Donnell PH; Massard C; Arkenau HT; Friedlander TW; Hoimes CJ; Lee JL; Ong M; Sridhar SS; Vogelzang NJ; Fishman MN; Zhang J; Srinivas S; Parikh J; Antal J; Jin X; Gupta AK; Ben Y; Hahn NM
    JAMA Oncol; 2017 Sep; 3(9):e172411. PubMed ID: 28817753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
    Mark M; Froesch P; Eboulet EI; Addeo A; Pless M; Rothschild SI; Janthur WD; Burmeister H; Friedlaender A; Schneider M; Metaxas Y; Joerger M; Wannesson L; Schwitter M; Baudoux N; Weindler S; Biaggi-Rudolf C; Früh M;
    Cancer Immunol Immunother; 2021 May; 70(5):1255-1262. PubMed ID: 33130956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
    Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
    JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
    Antonia SJ; Balmanoukian A; Brahmer J; Ou SI; Hellmann MD; Kim SW; Ahn MJ; Kim DW; Gutierrez M; Liu SV; Schöffski P; Jäger D; Jamal R; Jerusalem G; Lutzky J; Nemunaitis J; Calabrò L; Weiss J; Gadgeel S; Bhosle J; Ascierto PA; Rebelatto MC; Narwal R; Liang M; Xiao F; Antal J; Abdullah S; Angra N; Gupta AK; Khleif SN; Segal NH
    J Thorac Oncol; 2019 Oct; 14(10):1794-1806. PubMed ID: 31228626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
    Uldrick TS; Gonçalves PH; Abdul-Hay M; Claeys AJ; Emu B; Ernstoff MS; Fling SP; Fong L; Kaiser JC; Lacroix AM; Lee SY; Lundgren LM; Lurain K; Parsons CH; Peeramsetti S; Ramaswami R; Sharon E; Sznol M; Wang CJ; Yarchoan R; Cheever MA;
    JAMA Oncol; 2019 Sep; 5(9):1332-1339. PubMed ID: 31154457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
    Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
    JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    Borghaei H; Redman MW; Kelly K; Waqar SN; Robert F; Kiefer GJ; Stella PJ; Minichiello K; Gandara DR; Herbst RS; Papadimitrakopoulou VA
    Clin Lung Cancer; 2021 May; 22(3):178-186. PubMed ID: 33358401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
    Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
    BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
    Segal NH; Ou SI; Balmanoukian A; Fury MG; Massarelli E; Brahmer JR; Weiss J; Schöffski P; Antonia SJ; Massard C; Zandberg DP; Khleif SN; Xiao F; Rebelatto MC; Steele KE; Robbins PB; Angra N; Song X; Abdullah S; Butler M
    Eur J Cancer; 2019 Mar; 109():154-161. PubMed ID: 30731276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
    Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
    Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    Massard C; Gordon MS; Sharma S; Rafii S; Wainberg ZA; Luke J; Curiel TJ; Colon-Otero G; Hamid O; Sanborn RE; O'Donnell PH; Drakaki A; Tan W; Kurland JF; Rebelatto MC; Jin X; Blake-Haskins JA; Gupta A; Segal NH
    J Clin Oncol; 2016 Sep; 34(26):3119-25. PubMed ID: 27269937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
    Zamarin D; Walderich S; Holland A; Zhou Q; Iasonos AE; Torrisi JM; Merghoub T; Chesebrough LF; Mcdonnell AS; Gallagher JM; Li Y; Hollmann TJ; Grisham RN; Erskine CL; Block MS; Knutson KL; O'Cearbhaill RE; Aghajanian C; Konner JA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.